HSPG2 and prostate cancer: Immunohistochemical analysis for Perlecan in prostate cancer tissue microarrays with 600 patient samples demonstrated that Perlecan, a secreted proteoglycan, is present in the lumens of 54% of malignant prostate cancer glands, but not in normal glands (Figure.